Disruption of apoptotic pathways belongs to commonly reported molecular mechanisms that underlie cancer drug resistance. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, Apo2L) is a cytokine of the TNF family with selective anti-tumor activity and minimal toxicity toward healthy tissues. Primary leukemia cells are, however, largely intrinsically resistant to TRAIL-induced apoptosis. In this study we analyzed molecular differences between TRAIL-resistant K562 cell line and TRAIL-sensitive K562 clones. We demonstrate that TRAIL-sensitive K562 cells differ from the TRAILresistant cell line by cell surface downregulation of TRAIL decoy receptor 1, upregulation of both TRAIL death receptors, enhanced assembly and improved functioning of the death-inducing signaling complex, and increased cytoplasmic protein expression of CASP8 and key proapoptotic BCL2 members BID, BIM, BAD and BAK. The molecular basis of the intrinsic leukemia cell TRAIL resistance thus appears a consequence of the multi-level disruption of the extrinsic apoptotic pathway. The results of this study also suggest that the leukemia TRAIL-resistance is functional, leaving a possibility of overcoming the resistance by preexposure of the leukemia cells to potent TRAIL sensitizers, e.g. BH3-mimetics.
Intrinsic drug resistance represents one of the main obstacles in cancer therapy. Evading apoptosis through impairment of apoptotic pathways belongs to the commonly reported molecular mechanisms that underlie drug resistance. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, Apo2L) is a cytokine of the TNF family with selective anti-tumor activity and minimal toxicity toward healthy tissues. TRAIL binds to two death receptors (TRAIL-R1/DR4, TRAIL-R2/DR5) and two decoy receptors (TRAIL-R3/DcR1, TRAIL-R4/DcR4) [1, 2] . Ligation of TRAIL death receptors leads to formation of the death-inducing signaling complex (DISC) composed of the TRAIL, death receptors, core adapter protein FADD, initiator caspases CASP8 and CASP10, and FLIP, a competitive inhibitor of CASP8/10. Activated initiator caspases cleave and activate effector caspases CASP3, 6 and 7, as well as the proapoptotic BCL2 member BID. Truncated BID (tBID) in turn amplifies the proapoptotic signal through the mitochondria [3] . This amplification of the apoptotic signaling from TRAIL death receptors is required in the majority of tumor cells (type II cells). Expression of TRAIL receptors was shown to correlate with prognosis in a variety of tumors, including hematologic malignancies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . In the last decade, TRAIL-induced apoptosis gained much attention as a potentially targeted anti-cancer therapy [14] . Unfortunately, the anti-tumor activity of both recombinant human TRAIL and anti-TRAIL-death receptor monoclonal antibodies proved to be limited in most reported clinical trials [15] [16] [17] [18] . Despite the disappointing clinical results published so far TRAIL might re-emerge as a promising treatment approach in the future, mainly because TRAIL death receptor-targeted therapy possesses favorable toxic profile, it can induce apoptosis in diverse premalignant cell subsets, and it can be largely augmented by pre-or co-treatment with various molecules called TRAIL sensitizers [14, [19] [20] [21] [22] [23] [24] [25] [26] . Moreover, bioengineered TRAIL molecules or monoclonal antibodies selectively targeting individual TRAIL death receptors with much greater efficacy might demonstrate more potent anti-tumor activity compared to recombinant TRAIL [27, 28] .
Primary myeloid leukemia cells are largely intrinsically resistant to TRAIL-induced apoptosis. Several molecular mechanisms responsible for the leukemia TRAIL resistance were reported up to now, including overexpression of TRAIL decoy receptors, overexpression of FLIP or altered expression of apoptosis regulators including BCL2 family members, heat-shock proteins or inhibitor of apoptosis (IAP) proteins [29] [30] [31] [32] [33] [34] [35] [36] [37] .
In the present study we analyzed the molecular nature of two TRAIL-sensitive K562 clones derived by limiting dilutions from the original TRAIL-resistant K562 cell line. We demonstrated that the TRAIL-sensitive clones differed from the TRAIL-resistant cell line by decreased expression of TRAIL decoy receptor 1, increased expression of both TRAIL death receptors, increased assembly and enhanced functioning of the DISC, and increased cytoplasmic expression of CASP8 and key proapoptotic BCL2 members BID, BIM, BAD and BAK. The molecular basis of leukemia cell TRAIL resistance thus appears a consequence of a multi-level disruption of the extrinsic apoptotic pathway.
Materials and methods
Cell culture. K-562 cell line was cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Peripheral blood samples were collected from patients with de novo diagnosed acute myeloid leukemia (AML, n = 5) and chronic myeloid leukemia (CML, n = 5) before therapy after obtaining informed consent according to the Declaration of Helsinki. Mononuclear cells were isolated by Ficoll-Paque (GE Healthcare) density-gradient centrifugation and cultured in IMDM supplemented with 30% FBS.
Establishment of TRAIL-sensitive cell clones. TRAILsensitive K562 clones were established by limiting dilution from the original TRAIL-resistant K562 cells. K562 cells were diluted to a final concentration of 5 cells per 1 ml, distributed onto 96-well plates (100uL per well) and examined under light microscope. Only wells that contained a single cell were used for clone selection. In 14 days the wells with grown K562 clones were split into two wells. While the former well of each K562 clone was exposed to 1000 ng/mL TRAIL, the latter well was maintained in fresh medium. The percentage of apoptotic cells was measured after 24 hours. Two clones with the highest sensitivity to TRAIL (designated S1, S2) were expanded and used in further experiments described in detail in this current report.
Flow cytometry and detection of apoptosis. Cell surface expression of TRAIL receptors was analyzed by flow cytometry (FACS Canto, Becton Dickinson, California, USA) using primary anti-TRAIL receptor antibodies (R&D Systems, Minnesota, USA) and secondary PE-conjugated antibodies (Jackson Immunoresearch Laboratories Inc., USA). Apoptosis was measured by flow cytometry using Annexin-V-FITC (Apronex Biotechnologies, Czech Republic) staining. The percentage of apoptotic cells was evaluated using the DIVA software.
Cell proliferation assay. Cells were distributed onto 96-well plate (5.000 cells per well) on day 1. On day 2 increasing concentrations of cytotoxic drugs imatinib, etoposide, doxorubicin, cytarabine, and bortezomib were added to particular wells. Cell proliferation was measured in triplicates using WST-8 Cell Proliferation Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA) according to the manufacturer's protocol.
DISC precipitation. Cell lysates for immunoprecipitation were prepared from 5 x 10 8 cells. Cells were precooled prior the addition of biotinylated TRAIL (final concentration 1000 ng/ml). After 15 minute incubation on ice the cells were divided into three equal fractions and quickly warmed to 37°C. Each fraction was incubated at 37°C and analyzed at 0, 10 and 30 minutes after warming (i.e. 0 minutes = precipitation after 15 minute exposure to biotinylated TRAIL on ice). Cells were lyzed, and protein content of each sample was assessed using Bradford method. After equilibration of protein content, streptavidin-agarose beads were added to each sample and precipitated in cold room at 4°C for one hour. Beads were then separated by centrifugation and washed 5x. Finally, protein complexes were eluted by incubating samples in a heating block at 95°C for 15 minutes and agarose beads were removed by centrifugation. Protein precipitates were used for subsequent immunoblotting.
Western blot analysis. Cell lysates were resolved by electrophoresis using Novex ® NuPAGE ® 10% Bis-Tris Mini Gels (Life Technologies TM , Carlsbad, CA, USA) and transferred to PVDF membranes using iBlot ® Dry Blotting System (Life Technologies TM , Carlsbad, CA, USA). Blocking of non-specific binding sites was performed by incubation in 0.1% PBS-Tween 20 and fat-free dry milk (5%). Membranes were incubated with specific primary antibody overnight at 4°C, followed by washing in PBS and incubation with HRP-conjugated secondary antibody at room temperature for 1 hour. Obtained immunoblots were developed by the enhanced chemiluminescence (ECL) reagent kit (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) according to the manufacturer's protocol.
Primary antibodies used in this study were as follows (with dilutions used in the experiments): Beta-actin (I19) Santa Cruz, 43kDa, goat (1:1000); Caspase 2 (C20), Santa Cruz, 51kDa, rabbit (1:200); Caspase 3 (31A1067) Alexis, 32kDa, mouse (1:1000); Caspase 8 (12F5), Alexis, 55/54kDa, mouse (1:1000); Caspase 9 (5B4), MBL, 45/37/35kDa, mouse (1:500); Caspase 10 (4C1), MBL, 58/57kDa, mouse (1:500); BAD (C7), Santa Cruz, 25kDa, mouse (1:500); BAK (3814S), Cell Signaling, 25kDa, rabbit (1:1000); BID (5C9) Santa Cruz, 22kDa, mouse Statistical analysis. Student´s t-test was applied to evaluate statistical significance of the observed differences between TNF-alpha-and TRAIL-induced apoptosis in TRAIL-sensitive clones S1 and S2 compared to the original K562 cell line.
Results
Primary AML and CML blasts express TRAIL receptors 1-3, and are inherently resistant to TRAIL-induced apoptosis. We analyzed proapoptotic activity of TRAIL using peripheral blood mononuclear cells obtained from patients with newly diagnosed acute myeloid leukemia (AML, n = 5) and chronic myeloid leukemia (CML, n = 5). We confirmed that all primary AML and CML blasts were indeed resistant to TRAIL-induced apoptosis showing less than 10% apoptosis after 24 hour exposure to 1000 ng/mL TRAIL (Fig. 1a) . We also demonstrated that the primary AML/CML blasts expressed both TRAIL death-receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5), as well as the decoy receptor 1 (TRAIL-R3/DcR1), but not the decoy receptor 2 (TRAIL-R4/DcR2) (Fig. 1b) .
TRAIL-sensitive K562 clones S1 and S2 show increased sensitivity to TNF-alpha, but not to cytotoxic agents imatinib, cytarabine, etoposide, doxorubicin, and bortezomib. To analyze the molecular basis of the observed TRAIL-resistance of myeloid leukemia blasts, we used K562 cell line, established from a patient with erythroleukemia progressed from CML, which is characterized by TRAIL-resistance and similar pattern of expression of TRAIL receptors compared to primary AML/CML blasts (Fig. 1b, 1c) . By limiting dilution approach we derived two TRAIL-sensitive K562 clones designated S1 and S2. In concordance with our previous study on HL60 cells [37] we demonstrated that the TRAIL-sensitive clones S1 and S2 were also more sensitive to TNF-alpha compared to the original K562 cell line (Fig. 1c) , but have retained sensitivity to selected anti-tumor agents imatinib, cytarabine, etoposide, doxorubicin or bortezomib (Fig. 2) .
TRAIL-sensitive K562 clones show marked cell surface downregulation of decoy receptor 1, slight upregulation of both death receptors, and increased recruitment and cleavage of CASP8 at the DISC after exposure to TRAIL. Flow cytometry analysis of TRAIL-sensitive clones S1 and S2 revealed marked downregulation of the cell surface decoy receptor 1, and slight upregulation of both TRAIL death receptors, while expression of both TNF receptors remained unchanged (Fig. 3a) . Analysis of death-inducing signaling complex (DISC) revealed comparable amounts of precipitated TRAIL-receptor 2 (DR5) in TRAIL-resistant K562 cells and TRAIL-sensitive clones S1 and S2 after exposure to biotinylated TRAIL (at all time-points) (Fig. 3b) . S1 and S2 clones, however, showed markedly increased binding of CASP8 to the DISC (at 0 minutes), as well as enhanced cleavage of CASP8 at 10 and 30 minutes after exposure to biotinylated TRAIL (Fig. 3b) . As the amounts of cleaved FLIP-L at 10 and 30 minutes appeared similar in all tested samples, CASP8 to FLIP ratio was significantly increased in TRAIL sensitive clones compared to the original K562 cell line (Fig. 3b) .
TRAIL-sensitive K562 clones show increased protein expression of several key proapoptotic BCL2 family members. In our recently published study by Molinsky et al. (20) we demonstrated that downregulation of antiapoptotic BCL2 molecules MCL1 and BCL-XL strongly sensitized K562 cells to TRAIL-induced apoptosis. We thus decided to analyze expression profile of key BCL2 members and other selected apoptosis regulators in TRAIL-sensitive K562 clones compared to TRAIL-resistant K562 cell line by western blotting. In both TRAIL-sensitive clones we found protein upregulation of proapoptotic proteins CASP8, BAD, BID, BIM, BAK, and upregulation of antiapoptotic BCL-XL (Fig. 4) . Downregulation of BCL2 and upregulation of XIAP was detected in clone S1, while downregulation of MCL1 was detected in S2 clone (Fig. 4) . TRAIL-resistance of leukemia cells [6, 35, 37, 38] . In this study we analyzed molecular mechanisms responsible for TRAILresistance of K562 cell line and the nature of TRAIL-sensitivity of two TRAIL-sensitive K562 clones (S1, S2) established by limiting-dilution approach from the original K562 cell line. Both TRAIL-sensitive K562 clones showed almost identical molecular changes compared to the original K562 cells, namely 1. marked downregulation of the decoy receptor 1 together with slight upregulation of both death receptors, 2. increased expression of cytosolic CASP8, enhanced recruitment of CASP8 to the DISC, and increased cleavage of CASP8 at the DISC, and 3. protein overexpression of key proapoptotic BCL2 members BID, BAD, BIM, and BAK, together with upregulation of BCL-XL (Fig. 3-4) . Each of these molecular changes, with the exception of BCL-XL, might contribute to the observed enhanced sensitivity of S1 and S2 clones to TRAIL. The molecular differences between TRAIL-resistant and TRAIL-sensitive K562 cells thus appeared to involve the extrinsic apoptotic pathway at three different levels: 1. the receptor level, 2. the DISC level, and 3. the mitochondria level.
Despite the fact that the precise role of the decoy receptors 1 and 2 in TRAIL-triggered apoptosis remains incompletely understood, most studies published so far supported their role in mediating TRAIL-resistance [9, 10, 10, 29, 30, [39] [40] [41] [42] [43] [44] . In this study, we observed cell surface downregulation of the decoy receptor 1 in both TRAIL-sensitive clones (Fig. 3a) . Surprisingly, analysis of the DISC after exposure to biotinylated TRAIL revealed that the amounts of precipitated death receptor 5 were comparable in TRAIL-resistant and TRAIL-sensitive K562 cells (Fig. 3b) . Recruitments of other key DISC components CASP8, FADD and FLIP, however, displayed significantly decreased levels in TRAIL-resistant K562 cells (Fig. 3b) . While cleavage of CASP8 was significantly decreased in TRAILresistant K562 cells, the amounts of cleaved FLIP-L appeared similar in all analyzed samples (Fig. 3b) . We thus assume that the generation of large amounts of cleaved FLIP-L together with small amounts of cleaved CASP8 led to the functional blockage of propagation of apoptotic signal from the ligated TRAILR2/DR5 in K562 cell line.
In our previous study by Molinsky et al. [20] we demonstrated that targeted downregulation of a single anti-apoptotic protein MCL1 or BCL-XL, but not BCL2, was sufficient to fully sensitize K562 cells to TRAIL. We also showed that pretreatment with BH3-mimetic agent ABT-737 sensitized K562 cells to TRAIL. In this current study we reported significant upregulation of key proapoptotic BCL2 family proteins BID, BAD, BIM and BAK in TRAIL-sensitive K562 clones compared to TRAIL-resistant K562 cells (Fig. 4) . We assume that the consequences of either MCL1/BCL-XL downregulation/sequestration or BID/BAD/BIM/BAK upregulation are similar in that these molecular events induce permissive state of TRAILsensitivity by effectively amplifying proapoptotic signals from the TRAIL-ligated death receptors via the mitochondria. Based on the results of both our studies we suppose that changed expressions of BCL2 family members represent major molecular 
Discussion
Up to the present time a wide array of molecules and signaling pathways were reported as pivotal players mediating events that mediate TRAIL-sensitivity of K562 clones, while overexpression of cytoplasmic CASP8 and downregulation of cell surface decoy receptor 1 might contribute to the extent of TRAIL-sensitivity. We suppose that the increased DISC assembly and enhanced cleavage of CASP8 represent direct consequences of the changed expression of BCL2 proteins, CASP8 and DcR1.
In concordance with our previous study by Klener et al. [37] , restoration of the extrinsic apoptotic cascade in TRAILsensitive clones S1 and S2 was associated with increased sensitivity to TNF-alpha, another important proapoptotic cytokine (Fig. 1c) . In contrast, susceptibility of the clones remained unchanged to all of the tested anti-tumor drugs including imatinib (targeted agent: inhibitor of BCR-ABL tyrosine kinase), cytarabine (genotoxic agent: antinucleotide), etoposide (genotoxic agent: inhibitor of topoisomerase), doxorubicin (genotoxic agent: intercalating agent) and bortezomib (targeted agent: inhibitor of proteasome) (Fig. 2) . The reason, why the observed proapoptotic changes in the protein expression of several key BCL2 molecules were not associated with increased sensitivity to tested cytotoxic or targeted agents remains a conundrum. In the study by Molinsky et al. [20] we demonstrated that roscovitine, a cyclin-dependent kinase inhibitor, sensitized K562 cells (as well as primary AML/CML blasts) to TRAIL-induced apoptosis, and that this sensitization was associated with changed profile of BCL2 proteins. Despite the fact that pretreatment with roscovitine restored sensitivity of K562 cells to TRAIL and TNF-alpha, it did not increase sensitivity of the cells to commonly used cytotoxic agents. This finding was very similar compared to the results observed in this report. Precise molecular mechanisms, by which changed profile of BCL2 proteins at the mitochondria might selectively augment receptor-triggered apoptosis, remain to be elucidated.
In conclusion, inherent TRAIL-resistance of K562 cells (and potentially of AML and CML blasts) appears a consequence of multi-level disruption of the extrinsic apoptotic pathway. The results of this study also suggest that the leukemia TRAILresistance is functional (not structural), leaving a possibility of overcoming the resistance by preexposure of the leukemia cells to potent TRAIL sensitizers, e.g. BH3-mimetics.
